ABSTRACT
OBJECTIVES: The availability of doravirine (DOR) allowed clinicians to prescribe a dolutegravir (DTG)-based two-drug regimen (2DR) in individuals not eligible to receive lamivudine (3TC) or rilpivirine (RPV). The aims of this study were to describe the durability of DTG + DOR compared with DTG/3TC and DTG/RPV and the rate of virological failure and target not-detected maintenance over time. METHODS: This retrospective, monocentric analysis included all subjects who started a DTG-based 2DR from 2018 to 2022 as a simplification. Descriptive statistics and non-parametric tests to describe and compare the groups were applied. Kaplan-Meier probability curves and Cox regression models for regimens durability were used. RESULTS: The study enrolled 710 individuals: 499 treated with DTG/3TC, 140 with DTG/RPV, and 71 with DTG + DOR. A 2DR with DOR was prescribed to older subjects who had a longer infection, greater exposure to different antiretroviral regimens, a higher proportion of resistance-associated mutations, and a worse immune-virologic status. Over a cumulative follow-up of 68 152 weeks, 42 discontinuations were registered (5.9%). DTG + DOR had a risk of treatment interruption of 7.8% at 48 weeks and 9.8% at 96 weeks, significantly higher than the other 2DRs. In the multivariate Cox model, DTG + DOR and DTG/RPV were significantly associated with discontinuation. The maintenance of target not detected during follow-up was similar among groups. The rate of virological failure was higher for DTG + DOR through different event definitions. CONCLUSIONS: DTG + DOR durability was high over a long follow-up albeit lower than for other 2DRs. This combination might be an effective option in people with HIV that has proven difficult to treat.
Subject(s)
Anti-HIV Agents , Drug Therapy, Combination , HIV Infections , Heterocyclic Compounds, 3-Ring , Lamivudine , Oxazines , Piperazines , Pyridones , Triazoles , Humans , Retrospective Studies , Female , Male , HIV Infections/drug therapy , HIV Infections/virology , Heterocyclic Compounds, 3-Ring/therapeutic use , Heterocyclic Compounds, 3-Ring/administration & dosage , Adult , Middle Aged , Triazoles/therapeutic use , Triazoles/administration & dosage , Anti-HIV Agents/therapeutic use , Anti-HIV Agents/administration & dosage , Lamivudine/therapeutic use , Lamivudine/administration & dosage , Rilpivirine/therapeutic use , Rilpivirine/administration & dosage , Viral Load/drug effectsABSTRACT
HCV infection could have extrahepatic manifestations due to an aberrant immune response. HCV/HIV co-infection increases such persistent immune activation. Aim of the present study is to describe the evolution of inflammatory markers used in clinical practice, mixed cryoglobulinemia (MC) and autoantibody reactivity in co-infected individuals who achieved sustained virological response (SVR) after DAA treatment. This prospective, observational study included all HIV/HCV co-infected subjects who started any DAA regimen from 2015 to 2020. Samples for laboratory measurements (ferritin, C reactive protein, C3 and C4 fractions, rheumatoid factor, MC, anti-thyroglobulin Ab, anti-thyroid peroxidase Ab, ANCA, ASMA, anti-LKM, anti-DNA, AMA, ANA, T CD4+ and CD8+ cell count, and CD4/CD8 ratio) were collected at baseline, after 4 weeks, at end of treatment, and at SVR12. The analysis included 129 individuals: 51.9% with a F0-F3 fibrosis and 48.1% with liver cirrhosis. Cryocrit, C3 fraction, and rheumatoid factor significantly improved at week 4; ferritin, anti-thyroglobulin Ab, and C4 fraction at EOT; total leukocytes count at SVR12. MC positivity decreased from 72.8% to 35.8% (p < .001). T CD4+ cell slightly increased at SVR12, but with an increase also in CD8+ resulting in stable CD4/CD8 ratio. Autoantibody reactivity did not change significantly. ANA rods and rings positivity increased from 14.8% to 28.6% (p = .099): they were observed in three subjects without exposure to RBV. DAA therapy may lead to improvement in inflammatory markers and MC clearance but without significant changes in autoantibodies reactivity and CD4/CD8 ratio over a follow up of 12 weeks.
Subject(s)
Coinfection , HIV Infections , Hepatitis C, Chronic , Humans , Antiviral Agents/therapeutic use , Coinfection/drug therapy , HIV Infections/complications , HIV Infections/drug therapy , Rheumatoid Factor , Prospective Studies , Hepatitis C, Chronic/drug therapy , Sustained Virologic Response , Autoantibodies/therapeutic use , Hepacivirus/genetics , Treatment OutcomeABSTRACT
The treatment of visceral leishmaniasis (VL) is poorly standardized in Italy in spite of the existing evidence. All consecutive patients with VL admitted at 15 Italian centers as inpatients or outpatients between January 2004 and December 2008 were retrospectively considered; outcome data at 1 year after treatment were obtained for all but 1 patient. Demographic characteristics, underlying diseases, diagnostic procedures, treatment regimens and outcomes, as well as side effects were recorded. A confirmed diagnosis of VL was reported for 166 patients: 120 (72.3%) immunocompetent, 21 (12.6%) patients with immune deficiencies other than HIV infection, and 25 (15.1%) coinfected with HIV. Liposomal amphotericin B (L-AmB) was the drug almost universally used for treatment, administered to 153 (92.2%) patients. Thirty-seven different regimens, including L-AmB were used. The mean doses were 29.4 ± 7.9 mg/kg in immunocompetent patients, 32.9 ± 8.6 mg/kg in patients with non-HIV-related immunodeficiencies, and 40.8 ± 6.7 mg/kg in HIV-infected patients (P < 0.001). The mean numbers of infusion days were 7.8 ± 3.1 in immunocompetent patients, 9.6 ± 3.9 in non-HIV-immunodeficient patients, and 12.0 ± 3.4 in HIV-infected patients (P < 0.001). Mild and reversible adverse events were observed in 12.2% of cases. Responsive patients were 154 (93.3%). Successes were 98.4% among immunocompetent patients, 90.5% among non-HIV-immunodeficient patients, and 72.0% among HIV-infected patients. Among predictors of primary response to treatment, HIV infection and age held independent associations in the final multivariate models, whereas the doses and duration of L-AmB treatment were not significantly associated. Longer treatments and higher doses of L-AmB were not able to significantly modify treatment outcomes either in the immunocompetent or in the immunocompromised population.
Subject(s)
Leishmaniasis, Visceral/drug therapy , Adolescent , Adult , Aged , Amphotericin B/therapeutic use , Antiprotozoal Agents/therapeutic use , Child , Female , Humans , Italy , Male , Middle Aged , Retrospective Studies , Treatment Outcome , Young AdultABSTRACT
Tenofovir disoproxil fumarate (TDF) is widely used in HIV-infected patients. It is associated with tubular toxicity, but its management is controversial. A possible strategy is to switch to a dual therapy based on lamivudine or emtricitabine (XTC) and protease inhibitors (PIs). A case-control study was designed to evaluate the switch to XTC + PI therapy in patients with TDF-related renal toxicity. A case was defined as a patient who was on TDF/XTC + PI and who switched to XTC + PI. A control was defined as a patient with the same clinical features who remained on TDF/XTC + PI. Twenty-one cases and 21 controls were included. After 48 weeks, no differences in efficacy were observed. No improvement in the glomerular filtration rate as estimated with the Cockroft-Gault formula (eGFR) was seen, but the number of times that patients had values below 60 ml/min was higher with standard TDF/XTC 1 PI treatment than with dual XTC + PI treatment. A switch to dual therapy could be an option for patients at risk of TDF-related renal damage with no relevant risk of virological or immunological failure.
Subject(s)
Adenine/analogs & derivatives , Deoxycytidine/analogs & derivatives , HIV Infections/drug therapy , Kidney Diseases/chemically induced , Lamivudine/therapeutic use , Organophosphonates/adverse effects , Protease Inhibitors/therapeutic use , Reverse Transcriptase Inhibitors/therapeutic use , Adenine/adverse effects , Adult , Aged , CD4 Lymphocyte Count , Case-Control Studies , Chi-Square Distribution , Deoxycytidine/therapeutic use , Drug Therapy, Combination , Emtricitabine , Female , HIV Infections/immunology , Humans , Kidney Diseases/immunology , Kidney Diseases/virology , Kidney Function Tests , Male , Middle Aged , Retrospective Studies , Reverse Transcriptase Inhibitors/adverse effects , Tenofovir , Viral LoadABSTRACT
OBJECTIVES: Cases of undiagnosed severe febrile rhabdomyolysis in refugees coming from West Africa, mainly from Nigeria, has been observed since May 2014. The aim of this study was to describe this phenomenon. METHODS: This was a multicentre retrospective observational study of cases of febrile rhabdomyolysis reported from May 2014 to December 2016 in 12 Italian centres. RESULTS: A total of 48 cases were observed, mainly in young males. The mean time interval between the day of departure from Libya and symptom onset was 26.2 days. An average 8.3 further days elapsed before medical care was sought. All patients were hospitalized with fever and very intense muscle aches. Creatine phosphokinase, aspartate aminotransferase, and lactate dehydrogenase values were abnormal in all cases. The rhabdomyolysis was ascribed to an infective agent in 16 (33.3%) cases. In the remaining cases, the aetiology was undefined. Four out of seven patients tested had sickle cell trait. No alcohol abuse or drug intake was reported, apart from a single reported case of khat ingestion. CONCLUSIONS: The long incubation period does not support a mechanical cause of rhabdomyolysis. Furthermore, viral infections such as those caused by coxsackievirus are rarely associated with such a severe clinical presentation. It is hypothesized that other predisposing conditions like genetic factors, unknown infections, or unreported non-conventional remedies may be involved. Targeted surveillance of rhabdomyolysis cases is warranted.
Subject(s)
Refugees , Rhabdomyolysis/diagnosis , Adult , Africa, Western , Aspartate Aminotransferases/metabolism , Creatine Kinase/metabolism , Female , Fever , Humans , L-Lactate Dehydrogenase/metabolism , Male , Nigeria , Retrospective Studies , Rhabdomyolysis/etiology , Young AdultABSTRACT
Patients with sarcoidosis are at risk of opportunistic infections both from the sarcoidosis itself and from steroid therapy. Steroid therapy by reducing cell-mediated immunity increases the risk of infection with intracellular organisms. We present a case of Leishmania infection in a 51-year-old Italian woman receiving prednisone for sarcoidosis. The patient lives in Liguria, a region in the northwest of Italy that is considered highly endemic for leishmaniasis. We would postulate that even though leishmaniasis is seen relatively infrequently in connection with sarcoidosis, the occurrence of this opportunistic infection is possible in patients living in areas endemic for such protozoa.
Subject(s)
Endemic Diseases , Leishmaniasis/complications , Leishmaniasis/diagnosis , Sarcoidosis/complications , Female , Humans , Leishmaniasis/immunology , Middle Aged , Prednisone/therapeutic use , Sarcoidosis/drug therapy , Sarcoidosis/immunologyABSTRACT
In today's society, immigration and travel has resulted in large-scale population movements. This poses an additional challenge to the clinician when he or she takes the patient's history. The differential diagnosis of any presentation would need to include any diseases endemic to the area where the patient had been in. Ghana is considered a holoendemic high-risk area for the transmission of malaria. Moreover, compound heterozygous inheritance of hemoglobin (Hb) S and HbC often occurs in this area. We present a case of mixed Plasmodium falciparum-Plasmodium malariae infection complicating HbSC disease in a 34-year-old Ghanaian immigrant. We postulate that the malaria infection has transformed the patient's silent combined hemoglobinopathies (HbS/HbC) into a syndrome resembling a sickle cell crisis.
Subject(s)
Hemoglobin SC Disease/diagnosis , Malaria/blood , Malaria/diagnosis , Plasmodium falciparum/isolation & purification , Plasmodium malariae/isolation & purification , Adult , Animals , Diagnosis, Differential , Emigration and Immigration , Ghana , Hemoglobin SC Disease/blood , Humans , Malaria/complications , Malaria, Falciparum/blood , Malaria, Falciparum/complications , Malaria, Falciparum/diagnosis , MaleABSTRACT
Ecuador is considered a holoendemic high-risk area for the transmission of cysticercosis. Moreover, the progression of human immunodeficiency virus (HIV) occurs worldwide. We present a case of simultaneous diagnosis of cysticercosis and HIV infection in a 22-year-old Ecuadorian immigrant. We would postulate that with the increasing HIV incidence in endemic areas of cysticercosis, the simultaneous diagnosis of both diseases is an event to be expected.
Subject(s)
Brain Diseases/diagnosis , HIV Infections/diagnosis , Neurocysticercosis/diagnosis , Adult , Albendazole/therapeutic use , Anthelmintics/therapeutic use , Antiretroviral Therapy, Highly Active , Brain Diseases/complications , Brain Diseases/diagnostic imaging , Brain Diseases/pathology , Diagnosis, Differential , Ecuador/ethnology , Emigration and Immigration , Female , HIV Infections/blood , HIV Infections/complications , Humans , Italy , Magnetic Resonance Imaging , Neurocysticercosis/complications , Neurocysticercosis/diagnostic imaging , Neurocysticercosis/pathology , Tomography, X-Ray ComputedABSTRACT
Occasionally, malaria may present with unusual signs and symptoms. We report a case of an uncommon presentation of Plasmodium falciparum infection in a 59-year-old Ethiopian immigrant, which initially presented with hyperglycaemia and multiple organ dysfunction syndrome (MODS). Reports of unusual presentations of malaria are few and cases of severe malaria with hyperglycaemia are rarely described. As hyperglycaemia is associated to most severe malaria and high mortality, our aim is to catch the attention of the physicians on this entity.
ABSTRACT
Rhinoscleroma is a chronic indolent granulomatous infection of the nose and the upper respiratory tract caused by Klebsiella rhinoscleromatis; this condition is endemic to many regions of the world including North Africa. We present a case of rhinoscleroma in a 51-year-old Egyptian immigrant with 1-month history of epistaxis. We would postulate that with increased travel from areas where rhinoscleroma is endemic to other non-endemic areas, diagnosis of this condition will become more common.
Subject(s)
Anti-Bacterial Agents , Ethmoid Sinus/pathology , Klebsiella pneumoniae , Rhinoscleroma , Staphylococcus aureus , Turbinates/pathology , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/classification , Biopsy , Epistaxis/etiology , Ethmoid Sinus/microbiology , Humans , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/isolation & purification , Magnetic Resonance Imaging/methods , Male , Microbial Sensitivity Tests/methods , Middle Aged , Rhinoscleroma/complications , Rhinoscleroma/diagnosis , Rhinoscleroma/drug therapy , Rhinoscleroma/etiology , Rhinoscleroma/physiopathology , Staphylococcus aureus/drug effects , Staphylococcus aureus/isolation & purification , Tomography, X-Ray Computed/methods , Treatment Outcome , Turbinates/microbiologyABSTRACT
We report a 40-year old man in Uganda with ulcerated skins lesions, hypotension, and anaphylaxis caused by bites of safari ants. Treatment was successful. Physicians should be aware of anaphylaxis caused by ant bites.
Subject(s)
Allergens/immunology , Anaphylaxis/prevention & control , Ants/chemistry , Insect Bites and Stings/immunology , Insect Repellents/pharmacology , Skin Diseases/chemically induced , Wasp Venoms/toxicity , Adult , Anaphylaxis/chemically induced , Animals , Drug Hypersensitivity , Humans , Immunoglobulin E/immunology , Immunoglobulin E/toxicity , Skin Diseases/immunology , Skin Diseases/prevention & control , Uganda , Wasp Venoms/immunology , Wasp Venoms/metabolism , Wasp Venoms/therapeutic useABSTRACT
We report on four cases of infection by the recently described species Mycobacterium parascrofulaceum. In two cases the mycobacterium was isolated from AIDS patients, while in the others it was responsible for pulmonary disease in elderly men. Our findings suggest that M. parascrofulaceum is an opportunistic pathogen, like many other nontuberculous mycobacterial species.